Author:
De Carmo Campos Ana,Cardoso Maria Luís,Vicente Astrid
Reference5 articles.
1. Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. Ubiquitous pharmacogenomics consortium. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347-56.
2. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24:350-62.
3. Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic factors and pharmacogenomics in adverse drug reactions. Int J Mol Sci. 2021;22:13302.
4. Giardina C, Cutroneo PM, Mocciaro E, Russo GT, Mandraffino G, Basile G, et al. Adverse drug reactions in hospitalized patients: results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Front Pharmacol. 2018;9:350.
5. Almeida F, Vicente AM, Calado P, Santos M, Carvalho AS, Águas C, et al. Estratégia Nacional para a Medicina Genómica - PT_MedGen: desafios e prioridades [relatórios científicos e técnicos]. Instituto Nacional de Saúde Doutor Ricardo Jorge, IP; 2022 [cited 2003 mai 20]. Available from: http://hdl.handle.net/10400.18/8259.